Aliases & Classifications for Myofibroma

MalaCards integrated aliases for Myofibroma:

Name: Myofibroma 12 43 15 17 71
Solitary Myofibromatosis 71
Uterine Fibroids 71
Lipoleiomyoma 12
Myolipoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4386
MeSH 43 D047708
SNOMED-CT 67 44598004
UMLS 71 C0042133 C1096309 C1266121 more

Summaries for Myofibroma

MalaCards based summary : Myofibroma, also known as solitary myofibromatosis, is related to myopericytoma and infantile myofibromatosis, and has symptoms including pelvic pain An important gene associated with Myofibroma is MB (Myoglobin), and among its related pathways/superpathways is Immune response_IL-6 signaling pathway. The drugs Leuprolide and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include breast, uterus and bone, and related phenotype is muscle.

Related Diseases for Myofibroma

Diseases related to Myofibroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 myopericytoma 31.0 SRF RELA
2 infantile myofibromatosis 30.9 MIR143 MB DES CD34 CALD1 C3orf62
3 pleomorphic lipoma 30.6 SERPINA3 CD34
4 liposarcoma 30.5 MB DES CD34
5 intravenous leiomyomatosis 30.4 DES CALD1
6 leiomyoma 30.4 S100A1 DES CD34
7 lipomatosis, multiple 30.4 SERPINA3 DES CD34
8 epulis 30.3 SERPINA3 DES
9 leiomyosarcoma 30.1 SERPINA3 S100A1 MB DES
10 mesenchymal cell neoplasm 29.9 SERPINA3 CD34 CALD1
11 neurofibroma 29.9 S100A1 F13A1 CD34
12 hemangiopericytoma, malignant 29.7 SERPINA3 F13A1 DES CD34 CALD1
13 spindle cell sarcoma 29.7 SERPINA3 DES CD34
14 congenital fibrosarcoma 29.6 VGLL2 SERPINA3 S100A1 DES
15 pseudosarcomatous fibromatosis 29.6 SERPINA3 DES CD34 CALD1
16 sarcoma, synovial 29.5 SERPINA3 DES CD34
17 connective tissue benign neoplasm 29.5 SERPINA3 CD34 CALD1
18 glomus tumor 29.4 S100A1 DES CD34 CALD1
19 histiocytoma 29.3 SERPINA3 MB CD34 CD1A
20 fibrous histiocytoma 29.3 SERPINA3 F13A1 DES CD34
21 neurilemmoma 29.2 SERPINA3 S100A1 DES CD34
22 fibroma 29.1 SERPINA3 S100A1 F13A1 DES CD34
23 mesenchymoma 29.0 SERPINA3 MB DES CD34 CALD1
24 smooth muscle tumor 28.8 SERPINA3 S100A1 DES CD34 CALD1
25 uterine corpus lipoleiomyoma 12.3
26 curry-jones syndrome 11.5
27 giant cell myocarditis 10.5 MB DES
28 malignant triton tumor 10.5 MB DES
29 thymus lipoma 10.5 MB CD1A
30 immune system organ benign neoplasm 10.5 MB CD1A
31 medullomyoblastoma 10.5 MB DES
32 botryoid rhabdomyosarcoma 10.5 MB DES
33 fibroblastic rheumatism 10.4 F13A1 DES
34 fibromatosis 10.4
35 alk+ histiocytosis 10.4 F13A1 CD1A
36 bone sarcoma 10.4 MB DES
37 exophthalmos 10.4
38 malignant fibrous histiocytoma of bone 10.4 DES CALD1
39 ectomesenchymoma 10.4 S100A1 DES
40 granuloma annulare 10.4 F13A1 CD1A
41 parachordoma 10.3 S100A1 DES
42 prostate embryonal rhabdomyosarcoma 10.3 MB CALD1
43 reticulum cell sarcoma 10.3 S100A1 DES
44 cellular leiomyoma 10.3 DES CALD1
45 bilateral retinoblastoma 10.3 MB DES
46 ossifying fibromyxoid tumor 10.3 S100A1 DES
47 congenital epulis 10.3 SERPINA3 DES
48 leiomyoma, uterine 10.3
49 cystic teratoma 10.3
50 teratoma 10.3

Comorbidity relations with Myofibroma via Phenotypic Disease Network (PDN):


Asherman's Syndrome Cervix Uteri Carcinoma in Situ
Chronic Salpingo-Oophoritis Endometriosis
Endometriosis of Ovary Female Stress Incontinence
Hemometra Ovarian Cancer
Salpingo-Oophoritis

Graphical network of the top 20 diseases related to Myofibroma:



Diseases related to Myofibroma

Symptoms & Phenotypes for Myofibroma

UMLS symptoms related to Myofibroma:


pelvic pain

MGI Mouse Phenotypes related to Myofibroma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.1 DES MB RELA S100A1 SRF VGLL2

Drugs & Therapeutics for Myofibroma

Drugs for Myofibroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
2
Dienogest Approved Phase 4 65928-58-7
3
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
4
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
5
Desogestrel Approved Phase 4 54024-22-5 40973
6
Ethanol Approved Phase 4 64-17-5 702
7
Ferrous fumarate Approved Phase 4 141-01-5
8
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
9
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
10
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
leucovorin Approved Phase 4 58-05-9 6006 143
13
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
14
Calcium carbonate Approved, Investigational Phase 4 471-34-1
15
Zinc oxide Approved Phase 4 1314-13-2
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
19
Goserelin Approved Phase 4 65807-02-5, 1233494-97-7 47725 5311128
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
22
Dinoprostone Approved Phase 4 363-24-6 5280360
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
25
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
26
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
27
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
28
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
29
Misoprostol Approved Phase 4 59122-46-2 5282381
30
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
31
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
32
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
35
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
39
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
40
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
43
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
46
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
47
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
48
Cobalamin Experimental Phase 4 13408-78-1 6857388
49
Fibrinolysin Investigational Phase 4 9004-09-5
50 Hormone Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 321)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
5 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
6 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
7 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
8 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
9 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
10 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
11 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
12 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
13 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
14 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
15 Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Completed NCT03308643 Phase 4 Oxytocin
16 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
17 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
18 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
19 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
20 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
21 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
22 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
23 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
24 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
25 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
26 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
27 Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women - 2018 Recruiting NCT04043520 Phase 4 GnRH antagonist;Estrogen Product;Placebo estradiol;Placebo GnRH antagonist
28 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
29 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
30 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
31 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Not yet recruiting NCT04132349 Phase 4 Ulipristal Acetate 5 mg
32 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
33 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
34 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
35 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
36 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
37 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
38 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
39 Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns Unknown status NCT01280045 Phase 3
40 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
41 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
42 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
43 Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT02925494 Phase 3 Estradiol/Norethindrone Acetate;Elagolix
44 Uterine Fibroids: Impact of Ulipristal Acetate 10 mg on ART Results Completed NCT02425878 Phase 3 Ulipristal Acetate;Placebo
45 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02691494 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
46 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02654054 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
47 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
48 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147197 Phase 3 Ulipristal acetate (UPA);Placebo
49 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147158 Phase 3 Ulipristal acetate (UPA);Placebo
50 EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids Completed NCT00100191 Phase 3

Search NIH Clinical Center for Myofibroma

Cochrane evidence based reviews: myofibroma

Genetic Tests for Myofibroma

Anatomical Context for Myofibroma

MalaCards organs/tissues related to Myofibroma:

40
Breast, Uterus, Bone, Skin, Prostate, Liver, Smooth Muscle

Publications for Myofibroma

Articles related to Myofibroma:

(show top 50) (show all 2983)
# Title Authors PMID Year
1
Predicting the Fibroid-Migratory Impact of UAE: Role of Pre-embolization MRI Characteristics. 61
31650245 2020
2
The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. 61
31665442 2020
3
Diagnostic Performance of MR Imaging-based Features and Texture Analysis in the Differential Diagnosis of Ovarian Thecomas/Fibrothecomas and Uterine Fibroids in the Adnexal Area. 61
32035760 2020
4
A Case of a Prolapsed Fibroid in a 12-Year-Old Girl. 61
31536802 2020
5
Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study. 61
31679806 2020
6
Non-malignant fibroblastic/myofibroblastic tumors in pediatric age group: Clues and pitfalls to the cytological diagnosis. 61
32034815 2020
7
Ultrasound assessment of uterine morphology in menorrhagia: case control study. 61
31352859 2020
8
THE MEDICAL DEVICE APPLIED TO UTERINE FIBROIDS MORCELLATION: ANALYSIS OF CRITICAL BIOLOGICAL ISSUES AND DRAWBACKS FROM A MEDICAL-LEGAL PROSPECTIVE. 61
32013843 2020
9
Uterine fibroids in menopause and perimenopause. 61
31834160 2020
10
Uterine fibroids increase time to pregnancy: a cohort study. 61
31821047 2020
11
Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study. 61
31392917 2020
12
MRI evaluation of endopelvic fascial swelling and analysis of influencing factors in patients with uterine fibroids after high-intensity focused ultrasound ablation. 61
32031430 2020
13
Successful management of preoperatively diagnosed torsion of a subserosal uterine fibroid by pneumoperitoneum laparoscopic single-port surgery. 61
31611476 2020
14
Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. 61
31882457 2020
15
Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids. 61
31958025 2020
16
Non-contrast enhanced MRI for assessment of uterine fibroids' early response to ultrasound-guided high-intensity focused ultrasound thermal ablation. 61
31778966 2020
17
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids. 61
32012826 2020
18
Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double-blind, randomized, phase II dose-finding study. 61
31956287 2020
19
The impact of uterine artery embolization on ovarian reserve: A systematic review and meta-analysis. 61
31370100 2020
20
Delphi Approach for the Design of an Intraoperative Blood Conservation Pathway for Open Myomectomy. 61
31296447 2020
21
VILAPRISAN, A NEW SELECTIVE PROGESTERONE RECEPTOR MODULATOR IN UTERINE FIBROID PHARMACOTHERAPY - WILL IT REALLY BE A BREAKTHROUGH? 61
31985366 2020
22
Putative human myometrial and fibroid stem-like cells have mesenchymal stem cell and endometrial stromal cell properties. 61
31913469 2020
23
Surgical treatment of fibroids for subfertility. 61
31995657 2020
24
Novel SRF-ICA1L Fusions in Cellular Myoid Neoplasms With Potential For Malignant Behavior. 61
31478943 2020
25
Vitamin D and uterine fibroids: preclinical evidence is in; time for an overdue clinical study! 61
32033736 2020
26
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. 61
31971678 2020
27
Epidemiology and management of uterine fibroids. 61
31960950 2020
28
Nonpersistent endocrine disrupting chemicals and reproductive health of women. 61
31970122 2020
29
Impact of evaluation in interventional radiology clinic prior to uterine artery embolization: changes in management. 61
31897679 2020
30
Clinical Annotation Research Kit (CLARK): Computable Phenotyping Using Machine Learning. 61
32012059 2020
31
Incidental sonographic detection of bladder cancer in a woman with large uterine fibroids: significance and lessons learned. 61
31945687 2020
32
A rare pericytic tumor of the kidney: The first case in Korea. 61
31855704 2020
33
Bilateral abdominopelvic lymphoceles secondary to huge uterine leiomyomas: A case report. 61
31642137 2020
34
Uterine Artery Embolisation for Women with Giant Versus Non-giant Uterine Fibroids: A Systematic Review and Meta-analysis. 61
31792586 2019
35
Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies. 61
31702440 2019
36
Prescription of Chinese herbal products is associated with a decreased risk of uterine fibroids: A population-based cohort study. 61
31860966 2019
37
Use of the base purse-string suture approach to remove giant uterine fibroids during cesarean section. 61
31889467 2019
38
The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies. 61
31452302 2019
39
Guizhi Fuling Wan for uterine fibroids: A systematic review of in vivo studies. 61
31445128 2019
40
Influence of Ethnicity on Clinical Presentation and Quality of Life in Women With Uterine Fibroids: Results From a Prospective Observational Registry. 61
31882290 2019
41
Oxytocin-Augmented and Non-Sedating High-Intensity-Focused Ultrasound (HIFU) for Uterine Fibroids Showed Promising Outcome As Compared To HIFU Alone or Uterine Artery Embolization. 61
31493956 2019
42
Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire: a Chinese translation and validation study. 61
31796639 2019
43
Contributors to Racial Disparities in Minimally Invasive Hysterectomy in the US Department of Veterans Affairs. 61
31730567 2019
44
Google searches and medical publication trends since the 2014 US Food and Drug Administration position on power morcellation: Do these translate into patient awareness? 61
31715456 2019
45
Comparison between single-site and multiport robot-assisted myomectomy. 61
30666510 2019
46
Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial. 61
31502668 2019
47
The cost to perform uterine fibroid embolisation in the Australian public hospital system. 61
31793208 2019
48
Magnetic Resonance-Guided Focused Ultrasound: A Brief Review With Emphasis on the Treatment of Extra-abdominal Desmoid Tumors. 61
30807547 2019
49
Ginsenoside Rb1 inhibits proliferation and promotes apoptosis by regulating HMGB1 in uterine fibroid cells. 61
31313594 2019
50
Disseminated peritoneal leiomyomatosis: a devastating sequelae of unconfined laparoscopic morcellation. 61
31889207 2019

Variations for Myofibroma

Expression for Myofibroma

Search GEO for disease gene expression data for Myofibroma.

Pathways for Myofibroma

Pathways related to Myofibroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.14 SRF RELA

GO Terms for Myofibroma

Biological processes related to Myofibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.96 SRF RELA
2 negative regulation of pri-miRNA transcription by RNA polymerase II GO:1902894 8.62 SRF RELA

Sources for Myofibroma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....